Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a health diagnostics company headquartered in Salt Lake City, Utah, focused on precision pregnancy care and the early prediction of spontaneous preterm birth. News about Sera often centers on its PreTRM® Test, a blood-based biomarker test that provides individualized risk prediction for preterm birth in asymptomatic singleton pregnancies, and on the growing clinical and payer interest in this approach.
On this page, readers can find updates on Sera’s clinical research, including results and publications from the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study. Company press releases describe how the PRIME randomized controlled trial evaluated the PreTRM Test combined with targeted interventions and reported reductions in very early preterm births, NICU admissions, neonatal complications, and NICU length of stay compared with standard care.
SERA news coverage also includes quarterly financial results, payer and Medicaid pilot initiatives, and commentary on commercial progress for the PreTRM Test. The company has highlighted engagement with Medicaid plans and other organizations in multiple states, as well as presentations at medical and investor conferences where leadership discusses clinical data, health economic analyses, and market adoption efforts.
Investors and healthcare professionals following SERA can use this news feed to review announcements related to leadership appointments, conference presentations, regulatory filings summarized in press releases, and ongoing work to position pregnancy biomarker testing within prenatal care. Bookmark this page to access a consolidated view of Sera Prognostics’ latest press releases, study milestones, and business updates connected to its focus on improving outcomes for mothers and newborns.
Sera Prognostics has announced that their PreTRM® test-and-treat strategy has demonstrated significant improvements in neonatal health outcomes, as reported in the international journal Diagnostics. The AVERT PRETERM TRIAL showed an 18% reduction in severe neonatal morbidity and mortality, a 7-day reduction in the average hospital stay for neonates, a 2.48-week increase in gestational age for births before 32 weeks, and a 28-day reduction in hospital stays for neonates born before 32 weeks. These findings are significant for improving neonatal health in pregnancies previously considered low-risk. Additionally, the Data Safety and Monitoring Board has recommended stopping enrollment in the PRIME study due to meeting efficacy endpoints. Final results from this study are currently being analyzed.
Sera Prognostics (Nasdaq: SERA) has been added to the Russell 2000 and 3000 indexes following the 2024 annual reconstitution finalized on June 28, 2024. Effective today, the company joins the list of the 4,000 largest US stocks ranked by market capitalization as of April 30, 2024. Membership in the Russell 3000 Index entails automatic inclusion in the Russell 1000 or Russell 2000 indexes, along with relevant growth and value style indexes. The Russell indexes are significant benchmarks, used by investment managers and institutional investors, with $10.5 trillion in assets benchmarked as of December 2023. This inclusion marks a notable milestone for Sera Prognostics, enhancing its visibility among key financial stakeholders.
Sera Prognostics, specializing in maternal and neonatal health, announced its inclusion in the preliminary list for the Russell 2000 and Russell 3000 indexes. The Russell indexes, managed by FTSE Russell, include the top 4,000 US stocks based on market capitalization as of April 30, 2024. This inclusion is for one year and will give Sera exposure to investment managers and institutional investors who use these indexes as benchmarks, involving about $10.5 trillion in assets. Sera's President and CEO, Zhenya Lindgardt, sees this as a significant milestone in the company’s mission to enhance pregnancy-related healthcare.
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), reported its first-quarter 2024 financial results, focusing on improving maternal and neonatal health through innovative pregnancy biomarker information. The company highlighted submitting PRIME study interim analysis results for publication, launching ambient whole blood collection kits to reduce costs and increase lab processing efficiency, and expanding into international markets. Despite revenue adjustments, operational expenses decreased, resulting in a narrower net loss compared to the same quarter in 2023.
Sera Prognostics Inc., a company focused on improving maternal and neonatal health, will report first quarter fiscal year 2024 financial results on May 8, 2024. The conference call and webcast will discuss operational highlights, financial results, and key topics at 5:00 p.m. Eastern Time. Details for the call are provided for both US domestic and international callers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Sera Prognostics (SERA)?
What is the market cap of Sera Prognostics (SERA)?
